Search clinical trials for: Bintrafusp alfa (M7824)

Total 3075 results

National Cancer Institute (NCI)

Terminated

A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma

Urothelial Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).

Olfactory Neuroblastoma | Esthesioneuroblastoma | Neoplasm of the Nasal Cavity

United States
UNICANCER
Merck KGaA, Darmstadt, Germany

Terminated

Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma (ICING)

Squamous Cell Carcinoma of Head and Neck

France
AIO-Studien-gGmbH
Merck Serono GmbH, Germany

Terminated

Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer (NEOBIL)

Cholangiocarcinoma | Biliary Tract Cancer

Germany
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

Cholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer

Korea, Republic of, United States, Taiwan, Italy, France, China, Japan, Spain, United Kingdom
Fundación GECP

Recruiting

Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma (BIMES)

Mesothelioma; Lung

Spain
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer

Uterine Cervical Neoplasms

Korea, Republic of, United States, France, Belgium, China, Argentina, Spain, Australia, Russian Federation, Brazil, Hungary, Japan
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Bintrafusp Alfa Program Rollover Study

Cancer | Lung Cancer

Korea, Republic of, Spain, Germany, Japan, Taiwan, China, Italy, United States, Belgium, Russian Federation, Turkey, Ukraine
EMD Serono Research & Development Institute, Inc.
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt...

Terminated

Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

Triple Negative Breast Neoplasms

United States, France, Belgium, Spain, Russian Federation, Italy
Olivia Newton-John Cancer Research Institute
Austin Health; Merck Healthcare KGaA

Terminated

Bioimaging Study of 89Zr-M7824 in NSCLC

Non-Small Cell Lung Cancer

Australia
Academisch Medisch Centrum - Universiteit van Amsterdam...

Recruiting

Tapestry: Addition of TGF-β and PDL-1 Inhibition to Definitive Chemoradiation in Esophageal Squamous Cell Carcinoma (TAPESTRY)

Neoplasm, Esophageal | Neoplasm, Esophagus | Malignant Esophagus Tumor

Netherlands
National Cancer Institute (NCI)

Completed

Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

Head and Neck Cancer | Head and Neck Neoplasms

United States
National Cancer Institute (NCI)

Terminated

Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Metastatic Pancreatic Cancer | Histologically or Cytologically Confirmed Pancreatic Cancer | Unresectable or Borderline Resectable Pancreatic Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability

Metastatic Malignant Solid Neoplasm | Stage IV Colon Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Stage IVA Colon Cancer AJCC v8 | Stage IVA Rectal Cancer AJCC v8 | Stage IVB Colon Cancer AJCC v8 | Stage IVB Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Colon Adenocarcinoma | High-Frequency Microsatellite... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer

Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Resectable Lung Non-Small Cell Carcinoma | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditions

United States
Queen Mary University of London

Not yet recruiting

Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder (PEBBLE)

Transitional Cell Carcinoma | Bladder Cancer
GlaxoSmithKline
Merck KGaA, Darmstadt, Germany

Terminated

A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer

Neoplasms

Spain, United States, France, Netherlands, Canada
The University of Hong Kong
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt...

Completed

Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC

Nasopharyngeal Carcinoma | Metastatic Cancer | Recurrent Carcinoma | Non-keratinizing Carinoma

Hong Kong
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditions

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

First in Human Study of M6223

Metastatic Solid Tumors

United States, Canada
Haider Mahdi

Not yet recruiting

Antitumor Activity of Neoadjuvant Chemotherapy With or Without BINTRAFUSP ALFA in Patients With Metastatic Advanced Stage Ovarian Cancer

Ovarian Cancer

United States
National Cancer Institute (NCI)

Withdrawn

N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

Castration Resistant Prostate Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma

United States
M.D. Anderson Cancer Center

Completed

Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Second Primary Squamous Cell Carcinoma of the Head and Neck

United States
M.D. Anderson Cancer Center

Active, not recruiting

Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)

Metastatic Cancer | Solid Tumors

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
M.D. Anderson Cancer Center

Completed

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

Hematopoietic and Lymphoid Cell Neoplasm | Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Melanoma | Stage IV Lung Cancer AJCC v8 | Metastatic... and other conditions

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)

Cervical Cancer

United States, Spain, Japan
National Cancer Institute (NCI)

Recruiting

Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma

Thymic Epithelial Tumor | Thymic Cancer | Recurrent Thymoma

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

Solid Tumors

Korea, Republic of, United States, Belgium, Spain, Italy, Taiwan, Canada, Australia, United Kingdom, Germany, France, Japan
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States, Belgium, France
National Cancer Institute (NCI)

Recruiting

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

Cervical Cancer | Vulvar Cancer | Colon Cancer | Anal Cancer | Vaginal Cancer | Oropharyngeal Cancer | Penile Cancer | HPV | Human Papillomavirus | Neck Cancer

United States
National Cancer Institute (NCI)

Terminated

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Hormone Receptor Negative Breast Cancer | HER2+ Breast Cancer

United States
Institut Bergonié
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt...

Recruiting

Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma (TRUST)

Advanced Soft-tissue Sarcoma | Metastatic Soft-tissue Sarcoma

France
National Cancer Institute (NCI)

Completed

M7824 in People With Recurrent Respiratory Papillomatosis

Human Papilloma Virus | Recurrent Respiratory Papillomatosis | Laryngeal Papilloma, Recurrent | Respiratory Papillomatosis

United States
National Cancer Institute (NCI)

Completed

M7824 in Subjects With HPV Associated Malignancies

Cervical Cancer | Anal Cancer | Oropharyngeal Cancer | Human Papilloma Virus | Vaginal or Penile Cancer

United States
Merck KGaA, Darmstadt, Germany

Completed

MSB0011359C (M7824) in Subjects With Metastatic or Locally Advanced Solid Tumors

Solid Tumors

Korea, Republic of, Taiwan, Japan
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Active, not recruiting

A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

Hemophilia A

Spain, United States, Denmark, Italy, Taiwan, Malaysia, Belgium, Thailand, Turkey, Austria, Bulgaria, Canada, Finland, France, Germany, Hong Kong, Hungary, Korea, Republic of, Netherlands, Norway, Singapore, Ukraine, United Kingdom
National Cancer Institute (NCI)

Withdrawn

Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

Pulmonary Metastases | Germ Cell Tumors | Sarcomas | Melanomas | Epithelial Malignancies (Excluding Lung and Renal Cell Carcinomas)

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...
University Medical Center Groningen; UMC Utrecht; Erasmus Medical Center; Catharina... and other collaborators

Recruiting

TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY (TAPESTRY)

Carcinoma, Squamous Cell | Oesophageal Cancer

Netherlands
M.D. Anderson Cancer Center

Withdrawn

Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | Hormone Receptor Positive Breast Adenocarcinoma | Metastatic HER2 Negative Breast Adenocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

Kaposi Sarcoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Combination Immunotherapy in Biochemically Recurrent Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

Cervical Cancer | Anal Cancer | Oropharyngeal Cancer | HPV Cancers | Vulvar, Vaginal, Penile, Rectal Cancer

United States
National Cancer Institute (NCI)

Recruiting

Bintrafusp Alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

Urogenital Neoplasms | Bladder Cancer | Urothelial Cancer | Genitourinary Cancer | Urogenital Cancer

United States
Shire

Completed

Safety Study of Replagal® Therapy in Children With Fabry Disease

Fabry Disease

United States
Amgen

Completed

Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.

Anemia
Jonsson Comprehensive Cancer Center
Amgen

Completed

Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer

Lymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Precancerous/Nonmalignant Condition

United States

Search clinical trials for: Bintrafusp alfa (M7824)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations